Last updated: August 4, 2026
Octocaine 50 is a dental local anesthetic containing lidocaine hydrochloride 2% and epinephrine 1:50,000. Its commercial value is driven by reliable cartridge performance, injection comfort, shelf stability, and dental-distribution access rather than novel active-ingredient exclusivity. The strongest opportunities are preservative reduction, cartridge and packaging improvements, workflow differentiation, and regional supply agreements.
What is Octocaine 50 and how is it formulated?
Octocaine 50 is a sterile dental injection supplied in single-use cartridges. The active ingredients are lidocaine hydrochloride and epinephrine hydrochloride or epinephrine, depending on the product labeling convention. A typical 1.7 mL cartridge contains:
| Component |
Approximate amount per 1.7 mL cartridge |
Function |
| Lidocaine hydrochloride |
34 mg |
Local anesthetic |
| Epinephrine |
0.034 mg |
Vasoconstrictor; prolongs anesthesia and reduces systemic absorption |
| Sodium chloride |
Quantity sufficient |
Tonicity adjustment |
| Sodium metabisulfite or related sulfite |
Product-specific |
Epinephrine antioxidant |
| Water for injection |
Quantity sufficient |
Vehicle |
| Hydrochloric acid or sodium hydroxide |
Quantity sufficient |
pH adjustment |
The 1:50,000 epinephrine concentration equals 0.02 mg/mL. The formulation is intended for infiltration and nerve-block anesthesia in dentistry. Product labeling should control for exact cartridge fill volume, excipient identity, pH, preservative content, and storage conditions.
The formulation challenge is chemical stability. Epinephrine is susceptible to oxidation, especially in the presence of oxygen, light, elevated temperature, trace metals, and unsuitable pH. Lidocaine is comparatively stable, but the combined product must maintain potency, appearance, sterility, and container-closure integrity throughout shelf life.
What excipients protect Octocaine 50 stability?
The most important excipient function is epinephrine stabilization. Sulfite antioxidants are commonly used in epinephrine-containing injectable products because they limit oxidative degradation. This creates a direct tradeoff: sulfites improve product stability but can cause hypersensitivity reactions in susceptible patients, particularly those with asthma.
Excipient functions and development priorities
| Excipient or material |
Primary role |
Commercial and regulatory issue |
| Sodium metabisulfite or sodium bisulfite |
Antioxidant for epinephrine |
Must be disclosed prominently; sensitivity concerns |
| Sodium chloride |
Isotonicity |
Low technical risk; concentration affects injection comfort |
| Hydrochloric acid or sodium hydroxide |
pH control |
pH affects epinephrine stability, lidocaine comfort, and container compatibility |
| Water for injection |
Injectable vehicle |
Sterility and endotoxin control |
| Glass cartridge |
Primary container |
Breakage, delamination, extractables, stopper compatibility |
| Elastomeric plunger and seal |
Container closure |
Adsorption, leachables, oxygen ingress, dimensional fit |
| Nitrogen or low-oxygen headspace |
Oxidation control |
May improve stability but requires validated filling controls |
For a conventional Octocaine 50 product, the excipient strategy should focus on controlling oxygen exposure, metal contamination, pH drift, light exposure, and sulfite concentration. A lower sulfite level could create a marketing opportunity, but it would require long-term, accelerated, photostability, and in-use studies.
What formulation patents protect Octocaine 50?
The active ingredients in Octocaine 50 are old, widely used generic substances. Lidocaine was introduced decades ago, and epinephrine-containing dental anesthetic combinations have extensive prior art. The core composition is therefore unlikely to support meaningful new-product exclusivity.
The commercially relevant protection areas are narrower:
- A specific low-sulfite or sulfite-free composition.
- A defined pH range that improves epinephrine stability and injection tolerability.
- Oxygen-reduced cartridge filling and headspace control.
- A cartridge, stopper, or seal system that reduces leachables and oxygen ingress.
- A long-term stability profile at defined storage conditions.
- A premixed or unit-dose delivery system with improved dental workflow.
- A manufacturing process that reduces epinephrine degradation or particulate formation.
A patent directed only to "lidocaine plus epinephrine" would face substantial novelty and obviousness exposure. A stronger filing would combine a narrowly defined excipient system with measurable performance, such as improved epinephrine retention, reduced sulfite content, lower impurity growth, or extended stability.
When does Octocaine 50 lose exclusivity?
Octocaine 50 does not appear to depend on a modern composition-of-matter patent or biologic exclusivity period. The active ingredients and basic injectable combination are long-established. FDA exclusivity is therefore unlikely to create a meaningful barrier to competing lidocaine-epinephrine dental cartridges.
| Exclusivity category |
Relevance to Octocaine 50 |
| New chemical entity exclusivity |
Not applicable to lidocaine or epinephrine |
| Five-year NDA exclusivity |
Not expected for an old active-ingredient combination |
| Three-year clinical-investigation exclusivity |
Product-specific and unlikely to protect the established formulation |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No material product-specific barrier identified |
| Patent term extension |
No clear basis for the established combination |
| Biosimilar exclusivity |
Not applicable; Octocaine 50 is a small-molecule injectable |
The principal competitive barriers are manufacturing validation, FDA approval, dental-channel relationships, cartridge tooling, sterile supply, and product reliability.
What is the FDA regulatory status of Octocaine 50?
Octocaine 50 is regulated as a prescription injectable local anesthetic for dental use. The applicable regulatory requirements include:
- FDA drug approval or authorized marketing pathway for the specific product.
- Current Good Manufacturing Practice compliance.
- Sterility assurance and bacterial endotoxin controls.
- Stability data supporting labeled storage.
- Container-closure integrity.
- Extractables and leachables assessment.
- Labeling for sulfite sensitivity and vasoconstrictor precautions.
- Pharmacovigilance for local anesthetic systemic toxicity, cardiovascular events, and hypersensitivity.
The product should be evaluated against FDA requirements for injectable drug products and USP standards covering sterile products, particulate matter, bacterial endotoxins, container closure, and product-specific quality attributes. The precise FDA approval number, current manufacturer, and active labeling should be confirmed through the current Drugs@FDA and DailyMed records before a transaction, launch, or litigation position is formed.
Is Octocaine 50 listed in the Orange Book?
The Orange Book status depends on the specific approved application and the product’s listing under its legal applicant name. An Octocaine 50 trade name may not independently show the patent and exclusivity information associated with the underlying approved application.
For market-entry analysis, the relevant checks are:
| Orange Book issue |
Business significance |
| Approved application number |
Identifies the regulatory reference product |
| Patent listings |
Determines whether a Paragraph IV certification may be required |
| Use codes |
Defines the scope of any method-of-use patent |
| Exclusivity dates |
Establishes possible approval timing restrictions |
| Therapeutic-equivalence rating |
Indicates substitutability where listed |
| Applicant and labeler identity |
Separates brand ownership from contract manufacturing |
Because lidocaine and epinephrine are established actives, a generic applicant would more likely face formulation, manufacturing, or regulatory execution issues than a durable patent barrier.
Which companies are challenging Octocaine 50?
No major Paragraph IV challenge or high-profile federal patent litigation is inherently associated with the basic Octocaine 50 formulation. The market contains multiple dental anesthetic products using lidocaine with epinephrine, articaine with epinephrine, mepivacaine, prilocaine, and related local anesthetics.
Competitive pressure is more likely to arise from:
- Generic dental anesthetic manufacturers.
- Dental-supply distributors introducing private-label cartridges.
- Manufacturers of articaine products.
- Suppliers offering lower-cost imported cartridges.
- Firms with integrated dental anesthesia portfolios.
- Contract manufacturers seeking regional licensing or supply agreements.
A formal litigation review should distinguish between patent suits, product-liability cases, FDA warning letters, manufacturing recalls, and ordinary commercial disputes. These have different implications for market entry.
What commercial opportunities exist for an Octocaine 50 successor?
1. Sulfite-reduced formulation
A lower-sulfite product could target dentists who want to reduce sulfite exposure while retaining epinephrine stabilization. The opportunity is technically difficult because lower antioxidant content can shorten shelf life or increase impurity formation.
A credible product claim would require comparative data against the incumbent formulation, including:
- Epinephrine assay retention.
- Lidocaine assay retention.
- Oxidative impurity growth.
- Color change.
- Particulate formation.
- Stability after temperature excursions.
- Stability after light exposure.
- Cartridge-opening and injection performance.
2. Improved cartridge system
The cartridge is a major commercial differentiation point. Opportunities include:
- Reduced breakage.
- Improved plunger glide.
- Lower oxygen ingress.
- Better visibility of solution and particulates.
- More reliable aspiration.
- Compatibility with major dental syringes.
- Reduced dead volume.
- Improved labeling and color coding.
These improvements can support device or packaging patents even when the drug formulation itself is not patentable.
3. Low-pain injection positioning
Injection comfort depends on pH, tonicity, solution composition, needle quality, injection speed, and clinician technique. A buffered or pH-optimized product could provide a commercial advantage, but buffering can destabilize epinephrine and must be supported by stability data.
A strong development program would compare:
- Initial and end-of-shelf-life pH.
- Injection force.
- Osmolality.
- Local tolerability.
- Epinephrine degradation.
- Lidocaine potency.
- Clinical onset and duration.
4. Supply-chain reliability
Dental offices value consistent availability because anesthetic cartridges are routine consumables. A supplier with domestic or regional manufacturing, dual-source critical components, and stable distributor inventory could gain share without changing the active ingredients.
The strongest licensing targets may include dental distributors, private-label dental brands, and manufacturers that already sell needles, syringes, anesthetic cartridges, or infection-control products.
5. Portfolio conversion
Octocaine 50 can be positioned within a broader dental anesthesia portfolio:
| Product segment |
Strategic purpose |
| Lidocaine 2% with epinephrine 1:50,000 |
Hemostasis and short dental procedures |
| Lidocaine 2% with epinephrine 1:100,000 |
General-purpose dental anesthesia |
| Articaine 4% with epinephrine |
Strong tissue penetration and routine infiltration |
| Mepivacaine without vasoconstrictor |
Patients where vasoconstrictor avoidance is preferred |
| Prilocaine with or without vasoconstrictor |
Alternative local anesthetic profile |
| Topical anesthetic |
Pre-injection and pediatric workflow |
A portfolio strategy can lower customer acquisition costs and increase distributor leverage.
How strong is the patent estate for Octocaine 50?
The core patent estate is likely weak because the product relies on old active ingredients and a conventional injectable dosage form. The strongest protectable subject matter would be narrow and technical.
| IP category |
Estimated strategic strength |
| Lidocaine composition of matter |
Expired or commercially irrelevant |
| Epinephrine composition of matter |
Expired or commercially irrelevant |
| Basic lidocaine-epinephrine combination |
Weak |
| Conventional sulfite-containing formulation |
Weak to moderate, depending on claim specificity |
| Low-sulfite stability system |
Moderate if supported by unexpected data |
| Cartridge and closure design |
Moderate to strong if technically differentiated |
| Manufacturing process |
Moderate if difficult to replicate and claimable |
| Branding and trade dress |
Commercially useful but narrower than patent protection |
| Trade secrets |
Potentially meaningful for filling, oxygen control, and process parameters |
The best freedom-to-operate posture would avoid reliance on broad composition claims and instead combine regulatory approval, validated manufacturing, packaging know-how, trademarks, and distribution contracts.
What generic launch risks exist for Octocaine 50?
A generic entrant could potentially launch under an approved abbreviated pathway if the reference product and regulatory pathway support it. The main risks are:
- Inadequate epinephrine stability.
- Cartridge incompatibility with dental syringes.
- Visible discoloration or particulate formation.
- Container-closure failure.
- Insufficient sterility assurance.
- Supply interruptions for glass cartridges or elastomeric components.
- Labeling differences that reduce dental-office adoption.
- Distributor resistance to a single-product launch.
- Product liability exposure from dosing and vasoconstrictor warnings.
- Price erosion from private-label supply.
A successful launch should prioritize manufacturing consistency and channel access before aggressive price competition.
What licensing deals could create value?
Licensing opportunities are most credible in four structures:
- A formulation license for a reduced-sulfite or enhanced-stability product.
- A packaging license for an oxygen-resistant dental cartridge.
- A regional manufacturing and distribution agreement.
- A private-label agreement with a dental distributor.
Royalty economics would likely be stronger for an approved, differentiated product than for an early patent filing. A formulation-only asset without stability and regulatory data would have limited negotiating value because competitors can often design around broad claims.
Key Takeaways
- Octocaine 50 is a lidocaine 2% and epinephrine 1:50,000 dental injectable.
- Its core active-ingredient and conventional formulation protection is weak because the actives are old generic substances.
- Epinephrine oxidation is the central excipient and manufacturing problem.
- Sulfite reduction, oxygen control, pH optimization, and cartridge engineering offer the clearest product-development opportunities.
- The strongest commercial moat is likely to combine regulatory approval, validated sterile manufacturing, reliable cartridge supply, trademarks, and dental-distribution contracts.
- Paragraph IV and patent-litigation risk appear less important than regulatory execution, container compatibility, supply continuity, and pricing.
- The most attractive licensing targets are dental distributors, private-label brands, and manufacturers with established sterile cartridge capacity.
FAQs
Does Octocaine 50 contain sulfites?
Most epinephrine-containing dental anesthetic formulations use a sulfite antioxidant, such as sodium metabisulfite or sodium bisulfite, to limit epinephrine oxidation. The current product label should be used to verify the exact excipient.
Can Octocaine 50 be reformulated without epinephrine?
Yes, but removing epinephrine changes the clinical profile, including duration, systemic absorption, and hemostasis. The resulting product would be a separate formulation requiring its own regulatory and stability strategy.
Is articaine a direct commercial substitute for Octocaine 50?
Articaine with epinephrine competes directly in dental infiltration procedures. It is not an excipient-equivalent substitute because it uses a different active ingredient and concentration. Product selection depends on procedure, clinician preference, patient factors, and market availability.
Can a new Octocaine 50 cartridge receive patent protection?
A new cartridge may be patentable if it has a novel structure or measurable performance advantage, such as reduced oxygen ingress, improved plunger behavior, or better compatibility with dental syringes. A generic cartridge shape alone would face substantial patentability challenges.
What is the largest commercial risk for an Octocaine 50 competitor?
The largest risk is usually supply and quality execution rather than active-ingredient patent infringement. Sterility failures, epinephrine degradation, cartridge defects, and distributor stockouts can prevent adoption even when the regulatory filing is technically acceptable.
References
-
DailyMed. (n.d.). Lidocaine hydrochloride and epinephrine injection labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2009). Container closure systems for packaging human drugs and biologics: Guidance for industry. FDA.
-
U.S. Food and Drug Administration. (2015). Q1A(R2) stability testing of new drug substances and products. FDA.
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
-
Septodont. (n.d.). Octocaine 50 product information. Septodont.
